Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease

Abstract Background The treatment paradigm for metastatic hormone-sensitive prostate cancer (mHSPC) patients is evolving. PET/CT now offers improved sensitivity and accuracy in staging. Recent randomized trial data supports escalated hormone therapy, local primary tumor therapy, and metastasis-direc...

Descripció completa

Dades bibliogràfiques

Autors principals:	Neil R. Parikh, Claudia Huiza, Jill S. Patel, Sonny Tsai, Nathisha Kalpage, May Thein, Sage Pitcher, Steve P. Lee, Warren S. Inouye, Mark L. Jordan, Homayoon Sanati, Lida Jafari, Carol J. Bennett, Greg E. Gin, Amar U. Kishan, Robert E. Reiter, Michael Lewis, Ahmad Sadeghi, William J. Aronson, Isla P. Garraway, Matthew B. Rettig, Nicholas G. Nickols
Format:	Artigo
Idioma:	Inglês
Publicat:	BMC 2019-04-01
Col·lecció:	BMC Cancer
Matèries:	Oligometastases Prostate cancer Stereotactic body radiotherapy Abiraterone Apalutamide Leuprolide
Accés en línia:	http://link.springer.com/article/10.1186/s12885-019-5496-5
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!